Methylcitric Acid

This is not a routine metabolic marker. Methylcitric acid (often called methylcitrate, or MCA) shows up in your urine when one specific corner of your energy metabolism is broken. The two main conditions it points to are propionic acidemia (PA) and methylmalonic acidemia (MMA), inherited disorders where your body cannot properly break down certain protein building blocks and odd-chain fats.

If your urine MCA is meaningfully elevated, your body is producing something it normally would not. That single fact is the reason this test exists. It is mostly ordered to confirm, rule out, or monitor a known metabolic disorder, but it can also surface in adult-onset variants that look like other diseases on the surface, including unexplained kidney decline, cardiomyopathy, or neurologic symptoms.

What This Test Actually Measures

MCA is a tricarboxylic acid (a small acid with three carboxylic groups) that forms when an intermediate called propionyl-CoA piles up inside your cells. Normally, an enzyme called citrate synthase combines acetyl-CoA with oxaloacetate to make citric acid, the first step of the Krebs cycle (your cells' main energy production loop). When propionyl-CoA accumulates, that same enzyme grabs it instead and produces methylcitrate, which then leaks into blood and urine.

This matters because MCA is more than a passive marker. Once it builds up, it disrupts the Krebs cycle and impairs mitochondrial energy production (mitochondria are the energy-producing compartments inside your cells), which is part of why people with PA and MMA develop neurologic and kidney damage over time.

Where the Evidence Is Strongest

Methylcitric acid is one of the defining biochemical signatures of propionic and methylmalonic acidemia. In a follow-up cohort using dried blood spots (a dot of dried blood on filter paper) measured by tandem mass spectrometry, methylcitric acid was elevated in 100% of treated PA patients, 95.2% of isolated MMA patients, and 81.6% of combined MMA patients. Dried-blood-spot MCA correlated strongly with urine MCA in the same population, with a Spearman correlation around 0.69, where 1.0 would be a perfect match. These findings come from blood-spot measurements; the same studies show good correlation with urine, but most population-level cutoffs were developed in blood spots.

Outside these inherited disorders, urinary MCA has not been validated as a general health marker. The bulk of human evidence is in confirmed PA and MMA. If you are reading this and have never had a metabolic disorder workup, a clearly elevated result on this test is the kind of finding that pushes the workup forward, not something to file away.

Propionic Acidemia

Propionic acidemia is caused by a deficient enzyme called propionyl-CoA carboxylase. Of all the conditions that elevate MCA, this is the one where the signal is strongest and most consistent. Across published cohorts, MCA in PA is described as always very high and tightly tied to disease activity.

Higher MCA in PA tracks with more decompensation events (acute crises of metabolic instability), neurologic injury, and overall disease burden. After liver transplantation in 39 PA patients, median urinary methylcitrate fell from 35.4 to 15.2 within 6 months (p=0.03), and the C3 to C2 acylcarnitine ratio dropped from 1.4 to 0.8 (p=0.01). That is one of the cleanest demonstrations that the number on this test moves with the underlying biology.

Methylmalonic Acidemia

In MMA, the picture is similar but a step removed. The defect lies in an enzyme called methylmalonyl-CoA mutase (or its vitamin B12 partner), which is one step further down the propionate pathway than the PA defect. MCA is still elevated, but the more specific marker is methylmalonic acid itself.

In MMA cohorts, higher MCA aligns with lower kidney filtration rate (a measure called GFR), higher ammonia, more swings in toxic organic acids, and worse neurodevelopmental scores including lower IQ. After successful liver or liver-kidney transplantation, plasma MCA falls significantly across patients, paralleling the clinical improvement.

Late-Onset and Adult Presentations

Not every case of PA or MMA shows up in infancy. Milder genotypes can stay quiet for decades and surface in adulthood as dilated cardiomyopathy (an enlarged, weakened heart), kidney dysfunction, parkinsonism, dementia, or strokes that look unexplained on standard workups. Adult case reports describe MCEE gene mutations linked to elevated methylmalonic acid presenting alongside Parkinson's disease and dementia, and CblC defects presenting as adult-onset cardiomyopathy.

If you have an unexplained multisystem presentation, especially with kidney decline plus neurologic or cardiac symptoms, an organic acid profile that includes MCA is one of the tests that can help identify the cause.

Reconciling the Counterintuitive Part

This is not a high-equals-bad, low-equals-good marker for the general population. In a healthy adult with no inherited metabolic disorder, MCA should be very low or undetectable. There is no clinical meaning to a small fluctuation within the typical range. The interpretive weight comes from whether the value is clearly outside the floor that healthy controls live in. Think of this as a binary signal first (is there a propionate-pathway block?), and a graded severity marker second (in known PA/MMA, higher means more disease activity).

Tracking Your Trend

If you have a diagnosed propionate-pathway disorder or are working one up, serial testing matters more than a single reading. MCA fluctuates with metabolic stress, illness, and diet. In MMA, the magnitude and frequency of toxic-acid fluctuations correlate with worse neurodevelopment, not just the average level.

A reasonable pattern for someone actively managing a known condition or following up an abnormal initial result: get a baseline, retest within 3 to 6 months if you are changing diet or starting treatment, then track at least annually. For monitoring, MCA in dried blood spots and in urine track each other well enough that either matrix can be used, depending on what your clinical lab supports.

If Your Result Comes Back Out of Pattern

An isolated elevated urinary MCA should never be treated as a one-and-done finding. The decision pathway involves three steps in roughly this order:

• Confirm the pattern: repeat the urine organic acid analysis, ideally on a fresh sample, and add methylmalonic acid, propionylcarnitine (C3), and homocysteine. The combination tells you which branch of the pathway is involved.
• Investigate vitamin B12 status: vitamin B12 deficiency, whether acquired or genetic (cobalamin metabolism defects), can mimic this pattern. Serum B12, homocysteine, and methylmalonic acid together help separate genetic from acquired causes.
• Involve a metabolic specialist: if the pattern holds on repeat testing, a clinical geneticist or metabolic specialist should drive the next steps, which often include targeted gene sequencing for the propionate and cobalamin pathways.

When Results Can Be Misleading

A few things can shift this number in ways that do not reflect disease:

• Acquired vitamin B12 deficiency: can produce mild elevations in markers along the same pathway, but in newborn screening data, MCA was only modestly elevated in a small fraction of acquired B12 deficiency cases versus being markedly high in genetic disorders. A clearly elevated MCA is far more likely genetic.
• Pre-analytical handling: urinary organic acid analysis is sensitive to collection method, storage, and the specific lab technique used. Different labs use different methods, which is why a confirmatory test at the same reference lab is the right move before drawing conclusions.
• Acute illness or metabolic stress: in someone with a propionate-pathway disorder, MCA rises during illness or catabolic stress. A single high reading during an infection does not mean baseline disease has worsened.
• Hydration and urine concentration: untimed spot urines vary with hydration. Results are typically normalized to creatinine, but extreme dehydration or very dilute urine can still affect interpretation.